Data Portal @ linkeddatafragments.org

Matches in Ghent University Academic Bibliography for { <https://biblio.ugent.be/publication/01HDZVCY554FBDGTWZ5V7PPNAT> ?p ?o. }

• 01HDZVCY554FBDGTWZ5V7PPNAT classification C3.
• 01HDZVCY554FBDGTWZ5V7PPNAT date "2023".
• 01HDZVCY554FBDGTWZ5V7PPNAT language "eng".
• 01HDZVCY554FBDGTWZ5V7PPNAT type conference.
• 01HDZVCY554FBDGTWZ5V7PPNAT hasPart 01HDZVZR5VRA15P4504KXGAZTZ.pdf.
• 01HDZVCY554FBDGTWZ5V7PPNAT subject "Veterinary Sciences".
• 01HDZVCY554FBDGTWZ5V7PPNAT presentedAt urn:uuid:59e20653-5330-4ac2-b06d-dc18b57d8b8b.
• 01HDZVCY554FBDGTWZ5V7PPNAT abstract "The management of dogs with idiopathic epilepsy (IE) remains challenging, because antiseizure drugs (ASDs) are still unsuccessful in one third of the cases. Therefore, interest in innovative therapeutic targets, like the microbiota-gut-brain axis (MGBA) is increasing. Based on growing literature, the MGBA shows high potential with low associated risks and adverse effects. Therefore, the MGBA was targeted in a canine IE patient with a severe, drug-resistant phenotype via faecal microbial transplantation (FMT). A 1.5 years old female entire Cavalier King Charles Spaniel, diagnosed with IE (Tier II) at the age of 1 year, was presented at the UGent Small Animal Clinic for optimization of antiseizure management. At first presentation the dog received levetiracetam 23 mg/kg TID with a high mean seizure frequency (MSF). ASD management was adapted and phenobarbital 4.6 mg/kg BID was started, while tapering down levetiracetam. Reaching an optimal serum concentration of phenobarbital, MSF remained high and potassium bromide was added at 20 mg/kg BID but lowered to 15 mg/kg BID after 3 weeks due to side effects. The MSF did not decrease. Therefore, additional management options were discussed with the owner. Firstly, the diet was changed to a medium chain triglycerides diet (MCTD, Purina Neurocare®). Six weeks later MSF remained high and consequently FMT was performed. Fresh faeces was collected on the day of FMT together with frozen faeces the day before (to achieve an adequate amount), after donor screening. The resulting faecal slurry was given via a naso- oesophagal tube at a dose of 5g/kg. The dog was hospitalized for the procedure and received omeprazole (1 mg/kg) and metoclopramide (0,3 mg/kg) before FMT. The FMT procedure was well tolerated without adverse effects. Follow-up management included enteric coated capsules with lyophilised faeces from the same donor at 207 mg/kg twice weekly. This follow up treatment started 3 weeks after FMT, for a period of 12 weeks. Faecal samples were collected before FMT and at multiple timepoints after FMT for future assessment of the engraftment of the donor microbiome via 16sDNA sequencing. Ten weeks after the FMT, MSF showed a very mild but clinically irrelevant decrease. In conclusion, this case reports confirms safety and feasibility of FMT in a clinical case of canine IE. In this dog however, the effect on MSF was negligible. The lack of effect could be due to three main aspects. Firstly, the current protocol might have caused inadequate donor engraftment. 16sDNA sequencing will reveal performance of the protocol. Secondly, variable effects on MSF might be seen in different dogs, similar to medical and nutritional management of canine IE. Thirdly, the MGBA might not be an ideal target in the management of canine IE.".
• 01HDZVCY554FBDGTWZ5V7PPNAT author 4CBDBA34-2686-11E5-B10D-7DD3B4D1D7B1.
• 01HDZVCY554FBDGTWZ5V7PPNAT author CAED8556-2D6C-11E4-A9C7-B2F1B4D1D7B1.
• 01HDZVCY554FBDGTWZ5V7PPNAT author F459FAFE-F0ED-11E1-A9DE-61C894A0A6B4.
• 01HDZVCY554FBDGTWZ5V7PPNAT author F52858F4-F0ED-11E1-A9DE-61C894A0A6B4.
• 01HDZVCY554FBDGTWZ5V7PPNAT author F56EA566-F0ED-11E1-A9DE-61C894A0A6B4.
• 01HDZVCY554FBDGTWZ5V7PPNAT dateCreated "2023-10-30T08:32:26Z".
• 01HDZVCY554FBDGTWZ5V7PPNAT dateModified "2024-10-29T18:00:25Z".
• 01HDZVCY554FBDGTWZ5V7PPNAT name "Faecal microbial transplantation in a Cavalier King Charles Spaniel with drug-resistant idiopathic epilepsy".
• 01HDZVCY554FBDGTWZ5V7PPNAT sameAs LU-01HDZVCY554FBDGTWZ5V7PPNAT.
• 01HDZVCY554FBDGTWZ5V7PPNAT sourceOrganization urn:uuid:2419982c-a488-4e8c-8178-ef75ff90c415.
• 01HDZVCY554FBDGTWZ5V7PPNAT sourceOrganization urn:uuid:6a8b89a3-5a31-4712-bf0a-fe3c4d770ac6.
• 01HDZVCY554FBDGTWZ5V7PPNAT type C3.